NCT03394027View on ClinicalTrials.gov

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 17, 2018

Primary Completion Date

March 18, 2021

Study Completion Date

October 7, 2021

Conditions
Triple Negative Breast CancerEndometrial CancerHormone Receptor Positive, HER2 Negative Breast Cancer
Interventions
DRUG

ONC201

625 mg by mouth every 7 days; each cycle = 28 days. Patients will receive ONC201 as long as they derive clinical benefit or toxicity becomes impeditive.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT03394027 - ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma | Biotech Hunter | Biotech Hunter